TITLE

Can complementary medicine increase adherence to chemotherapy dosing protocol? A controlled study in an integrative oncology setting

AUTHOR(S)
Shalom-Sharabi, Ilanit; Lavie, Ofer; Samuels, Noah; Keinan-Boker, Lital; Lev, Efraim; Ben-Arye, Eran
PUB. DATE
December 2017
SOURCE
Journal of Cancer Research & Clinical Oncology;Dec2017, Vol. 143 Issue 12, p2535
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Context and objectives: The impact of complementary and integrative medicine (CIM) on adherence to chemotherapy regimens is unclear. We explored the effect of patient-tailored CIM treatments on the relative dose intensity (RDI) of chemotherapy among patients with breast and gynecological cancer. Methods: Chemotherapy-treated patients with breast or gynecological cancer were referred by their oncology healthcare professional to a CIM treatment program. Adherence to integrative care (AIC) was defined as ≥4 CIM treatments, with ≤30 days between each treatment. Relative dose intensity (RDI) of chemotherapy was compared between CIM-treated patients and controls, and among adherence sub-groups. Results: RDI was calculated for 106-treated patients (62 AIC) and 75 controls. Baseline-to-6-week RDI values were similar in both study arms, with a lower % RDI <1.0 among controls at 12 weeks (47 vs. 57.5%; P = 0.036). Adherence sub-groups had similar RDI values, though at 6 weeks, the AIC group had lower % RDI <1.0 (33.9 vs. 54.5%, P = 0.046). Total administered medication dose/planned dose was higher in the AIC group at 6 weeks for paclitaxel (82%/50%, P = 0.025) and carboplatin (87%/67%, P = 0.028), with no difference in cytoxan/adriamycin dosages. Conclusion: A patient-tailored CIM program for patients with breast or gynecological cancer may be associated with a lower percentage of reduced RDI at 6 weeks, this in a sub-group of patients with higher adherence to CIM, and for specific chemotherapy agents, though this benefit did not persist after 12 weeks. Further research is needed to better understand the impact of CIM in cancer care.
ACCESSION #
126306472

 

Related Articles

  • The Oncology Nursing Society Ambulatory Office Nurse Survey. Ireland, Anne M.; DePalma, Judith A.; Arneson, Linda; Stark, Laurel; Williamson, Judy // Oncology Nursing Forum;Nov2004, Vol. 31 Issue 6, pE147 

    Focuses on a survey by the Oncology Nursing Society on key areas of practice related to ambulatory and office nurses involved with chemotherapy administration. Overview of the study population; Key findings; Recommendations.

  • The anti-angiogenic basis of metronomic chemotherapy. Kerbel, Robert S.; Kamen, Barton A. // Nature Reviews Cancer;Jun2004, Vol. 4 Issue 6, p423 

    In addition to proliferating cancer cells and various types of normal cells, such as those of the bone marrow, conventional cytotoxic chemotherapeutics affect the endothelium of the growing tumour vasculature. The anti-angiogenic efficacy of chemotherapy seems to be optimized by administering...

  • Outcomes of ovarian stimulation after treatment with chemotherapy. Chan, Jessica; Johnson, Lauren; Efymow, Brenda; Sammel, Mary; Gracia, Clarisa // Journal of Assisted Reproduction & Genetics;Oct2015, Vol. 32 Issue 10, p1537 

    Purpose: Chemotherapeutic agents have a known gonadotoxic effect; however, it is difficult to predict the impact they may have on ovarian stimulation. The objective of this study was to evaluate response to ovarian stimulation in patients exposed to chemotherapy compared with patients who were...

  • Why Some Cancer Patients Choose Complementary and Alternative Medicine Instead of Conventional Treatment. Shumay, Dianne M.; Maskarinec, Gertraud; Kakai, Hisako; Gotay, Carolyn C. // Journal of Family Practice;Dec2001, Vol. 50 Issue 12, p1067 

    OBJECTIVES We examined cancer patients' reasons for declining all or part of recommended cancer treatment and choosing complementary and alternative medicine (CAM). STUDY DESIGN This was qualitative interview study. POPULATION Fourteen cancer survivors who reported having declined all or part o...

  • INCIDENCES, SCREENING AND CHEMOTHERAPY OF BREAST CANCER. Khaliq, Sheikh Abdul; Naqvi, Syed Baqir S.; Fatima, Anab // International Journal of Pharmacy;2013, Vol. 3 Issue 4, p705 

    Retrospective study in different ethnic groups determines the burden and patterns of breast cancers during the last eight years reported in Oncology wards of hospitals of Karachi, Pakistan and compares the pharmacotherapy/chemotherapy used with international guidelines, develops strategies for...

  • INCIDENCES, SCREENING AND MANAGEMENT OF PROSTATE CANCER. Khaliq, Sheikh Abdul; Khan, Zahid; Mallick, Atiquddin; Fatima, Anab // International Journal of Pharmacy;2014, Vol. 4 Issue 1, p34 

    Retrospective study in different ethnic groups determines the burden and patterns of prostate cancer during the last eight years reported in Oncology wards of hospitals of Karachi, Pakistan. Compares the management pharmacotherapy/chemotherapy/surgery with international guidelines, develops...

  • Oral Chemotherapy. Birner, Ann; Rezendes, Megan; Hogle, William P. // Clinical Journal of Oncology Nursing;Feb2005, Vol. 9 Issue 1, p107 

    Presents a test on oral chemotherapy for cancer nurses.

  • EXPERIENCE OF TREATMENT IN PATIENTS WITH GALLBLADDER CANCER USING DIFFERENT CHEMOTHERAPY REGIMENS. Kit, O. I.; Kasatkin, V. F.; Trifanov, V. S.; Vakareva, A. A. // Oncosurgery / Onkohirurgia;2012, Vol. 4 Issue 4, p31 

    Objective: to study immediate and long-term results of treatment in patents with gallbladder cancer. Materials and Methods: the study of one hundred thirty patients with gallbladder cancer (39 male and 91 female) treated in 1995-2012 in the Department of Thoraco-Abdominal Oncology of Rostov...

  • Avastin-Tarceva combination fails in lung cancer. Jones, Dan // Nature Biotechnology;Feb2009, Vol. 27 Issue 2, p108 

    The article gives perspective on research of combination drug therapies used in oncology by first reporting findings regarding the combined use of Genetech's Avastin and OSI Pharmaceutical's Tarceva. As reported at the Chicago Multidisciplinary Symposium in Thoracic Oncology in November 2008,...

  • To Combine or Not to Combine: Natural Health Products and Chemotherapy? Lemmo, Walter // Townsend Letter;Aug/Sep2006, Issue 277/278, p76 

    The article discusses the safety and efficacy of combining chemotherapy with intravenous antioxidant. In 1999, an article published in the journal "Oncology" has exposed probable concerns of combining chemotherapy with dietary antioxidant supplements. However, a study published in the "Journal...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics